[Stiripentol for the treatment of severe myoclonic epilepsy in infants (Dravet's syndrome)]
Mengarelli C, Bardach A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Ciapponi A, López A, Rey-Ares L
Record ID 32017000287
Spanish
Authors' recommendations:
There is low quality evidence from two small randomized clinical trials suggesting that stiripentol might reduce the rate of seizures in severe myoclonic epilepsy in infants (Dravet's syndrome). There is no evidence showing improvement in cognitive impairment or quality of life in this group of patients at long term.
This is a drug classified as "orphan drug", only approved in some European countries and Canada as adjuvant therapy in combination with clobazam and valproic acid for refractory generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in infants (Dravet's syndrome) whose seizures are not adequately controlled with clobazam and valproic acid.
The clinical practice guidelines and the health sponsors from Europe and Canada suggest adding stiripentol for patients with Dravet's syndrome whose treatment with valproic acid, clobazam or topiramate has not been successful.
Details
Project Status:
Completed
Year Published:
2017
URL for published report:
www.iecs.org.ar/home-ets/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Dioxolanes
- Epilepsies, Myoclonic
- Spasms, Infantile
- Infant
- Seizures
- Anticonvulsants
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
<p>Institute for Clinical Effectiveness and Health Policy (IECS)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.